Neo Ivy Capital Management Acquires New Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Neo Ivy Capital Management bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 67,936 shares of the company's stock, valued at approximately $1,252,000.

Several other hedge funds have also modified their holdings of the company. Quest Partners LLC lifted its position in shares of Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company's stock worth $81,000 after purchasing an additional 807 shares in the last quarter. CWM LLC increased its position in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company's stock valued at $110,000 after buying an additional 1,054 shares in the last quarter. Arizona State Retirement System increased its position in Hims & Hers Health by 3.0% during the 2nd quarter. Arizona State Retirement System now owns 40,344 shares of the company's stock worth $815,000 after purchasing an additional 1,173 shares in the last quarter. Victory Capital Management Inc. raised its stake in Hims & Hers Health by 6.6% in the 2nd quarter. Victory Capital Management Inc. now owns 19,469 shares of the company's stock valued at $393,000 after purchasing an additional 1,212 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its stake in shares of Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock valued at $37,000 after acquiring an additional 1,603 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Price Performance

Shares of NYSE HIMS traded down $1.05 during midday trading on Wednesday, reaching $29.82. The company's stock had a trading volume of 9,761,673 shares, compared to its average volume of 9,928,585. The stock has a market capitalization of $6.52 billion, a P/E ratio of 70.10 and a beta of 1.25. The firm has a 50 day moving average price of $24.05 and a 200-day moving average price of $20.73. Hims & Hers Health, Inc. has a 12-month low of $8.09 and a 12-month high of $35.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. During the same quarter last year, the business posted ($0.04) earnings per share. The firm's revenue was up 77.1% compared to the same quarter last year. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Activity at Hims & Hers Health

In other news, insider Michael Chi sold 2,054 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $33.56, for a total value of $68,932.24. Following the sale, the insider now owns 184,947 shares in the company, valued at $6,206,821.32. This represents a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Andrew Dudum sold 45,767 shares of Hims & Hers Health stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $16.33, for a total transaction of $747,375.11. Following the completion of the sale, the chief executive officer now owns 67,015 shares in the company, valued at approximately $1,094,354.95. This trade represents a 40.58 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 974,495 shares of company stock valued at $22,548,139 over the last 90 days. Corporate insiders own 17.71% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on HIMS. Deutsche Bank Aktiengesellschaft boosted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a report on Wednesday, November 6th. Needham & Company LLC began coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a "buy" rating and a $24.00 price target on the stock. Bank of America lowered Hims & Hers Health from a "buy" rating to an "underperform" rating and lowered their price target for the company from $32.00 to $18.00 in a report on Thursday, November 14th. TD Cowen reaffirmed a "buy" rating and set a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Finally, Canaccord Genuity Group increased their price target on Hims & Hers Health from $28.00 to $38.00 and gave the company a "buy" rating in a research report on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $21.43.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.